Nalpain: Nalbuphine Preparation as Mixed Opioid Agonist Antagonist
Nalpain is the brand name for the active substance nalbuphine, a synthetic opioid with a mixed agonist antagonist profile. Nalbuphine has been approved since 1979 and is used in pain management, anesthesia, and obstetrics. In Germany, nalbuphine is not approved for standard therapy, but it is established in some European countries (Spain, Poland, Czech Republic) as well as in the USA. Other international brand names are Nubain (USA, historical) and Nalpa (France).
The distinctive feature of nalbuphine lies in its activity profile: it acts as an agonist at the kappa opioid receptor and as an antagonist at the mu receptor. This results in analgesic potency comparable to morphine (in the low dose range), without the typical dose-dependent respiratory depression that is problematic with pure mu agonists such as morphine or fentanyl. However, nalbuphine has a ceiling effect, above a certain dose analgesia does not increase further, which limits its clinical use.
Mechanism of Action
Nalbuphine is a partial agonist at the kappa opioid receptor and simultaneously a partial antagonist at the mu opioid receptor. This combination produces dose-dependent analgesia through kappa activation without the pronounced respiratory depression, euphoria, and addiction potential of pure mu agonists.
Respiratory depression under nalbuphine is comparable to morphine in the low to moderate dose range, but due to the ceiling effect reaches a plateau and does not increase further at higher doses. This safety is a major advantage in obstetrics and in situations where rapid pain relief without extensive respiratory monitoring is desired.
Also important is the antagonism at the mu receptor: in patients on ongoing therapy with pure mu agonists (e.g. morphine, oxycodone), nalbuphine can antagonize analgesic effects and trigger withdrawal syndrome.
Pharmacokinetically, nalbuphine is poorly absorbed orally (first pass approximately 80 percent), therefore administration is intravenous, intramuscular, or subcutaneous. Half-life approximately 5 hours, elimination via renal and biliary routes.
Indications
- Moderate to severe pain: postoperative, post-traumatic, in malignant diseases
- Obstetrics: labor analgesia as an alternative to pethidine, with less respiratory depression in the newborn
- Anesthesia adjunctive medication: as an analgesic during ambulatory procedures or as an adjuvant
- Off-label for pruritus: effective for opioid-induced or cholestatic itching due to kappa activity
- Emergency medicine: used in some countries as a prehospital analgesic
Dosage and Administration
Adults: 10 to 20 mg intramuscularly or subcutaneously, every 3 to 6 hours as needed. Maximum single dose 20 mg, maximum daily dose 160 mg. Intravenously: 5 to 10 mg slowly, onset of action after 2 to 3 minutes.
Labor analgesia: 10 mg intravenously, may be repeated as needed. Prior to delivery, the effect should ideally have worn off to avoid respiratory depression in the newborn.
In renal and hepatic insufficiency: reduce dose. Children from 18 months: 0.1 to 0.2 mg/kg, individually adjusted.
Adverse Effects
Common: sedation, dizziness, nausea, vomiting, dry mouth, headache, sweating.
Occasional: dysphoria, hallucinations (typical for kappa agonists), confusion, tachycardia or bradycardia, blood pressure changes.
Severe, rare: respiratory depression in at-risk patients or overdose, paradoxical pain intensification in patients on ongoing mu agonist therapy, seizures, anaphylactic reactions, acute withdrawal syndrome in opioid-dependent patients.
Important: in pre-existing therapy with pure mu agonists or in opioid dependence, nalbuphine can antagonize analgesia and trigger withdrawal syndrome. Concomitant medication must be carefully assessed prior to use.
Drug Interactions
- Pure mu agonists (morphine, oxycodone, fentanyl): antagonism, loss of effect and withdrawal risk
- Other CNS depressants (benzodiazepines, alcohol, sedatives, antipsychotics): additive respiratory depression and sedation
- MAO inhibitors (tranylcypromine): theoretically enhanced effect, use caution
- Naloxone: antagonizes the effect, can be used for reversal in overdose
- Tramadol, pethidine: additive serotonergic effect possible
Special Precautions
Pregnancy and breast-feeding: in obstetrics, nalbuphine is preferred in some countries because respiratory depression in the newborn is less than with pethidine. With prolonged therapy in pregnancy there is risk of neonatal adaptation disorders. Use in breast-feeding is possible, monitor infant.
Controlled substance status: in Germany, nalbuphine is not subject to the Narcotic Drug Act, which facilitates prescribing compared to pure opioids. In the USA, it was previously listed under Schedule IV.
Opioid dependence: patients with opioid dependence or on substitution therapy (methadone, buprenorphine) should not receive nalbuphine due to antagonism. Careful history taking is mandatory.
Antagonism of respiratory depression: in suspected overdose, naloxone can be used, though higher doses are required than with pure mu agonists.
You Might Also Be Interested In
- Morphine, classic pure mu agonist
- Buprenorphine, partial mu agonist with substitution indication
- Pethidine, classic opioid in obstetrics
- Tramadol, weak opioid analgesic
- Naloxone, opioid antidote in overdose
Frequently Asked Questions
Why is nalbuphine not as widespread in Germany as in other countries?
In Germany, a broad range of well-established opioids is available for pain management and labor analgesia. Nalbuphine is not approved here, although it has an established position in some European countries and in the USA. In German obstetrics, epidural anesthesia, remifentanil PCA, or pethidine are usually used.
Does nalbuphine cause dependence?
Due to the partial mu antagonism and ceiling effect, the addiction potential is lower than with pure mu agonists such as morphine or oxycodone. In the USA, nalbuphine is no longer classified as a controlled substance; in Germany it is not subject to the Narcotic Drug Act. Dysphoric and hallucinogenic effects have been described with abusive use.
Why can nalbuphine help against itching?
Opioid-induced and cholestatic pruritus are partly mediated through central mu and kappa mechanisms. Nalbuphine acts as an antagonist at the mu receptor and can thereby reduce itching under morphine or in liver disease without complete loss of analgesia. Lower doses are used for this indication.
What is the ceiling effect?
Above a certain dose (approximately 30 mg per 70 kg), the analgesic effect of nalbuphine does not increase further; additional doses only increase adverse effects. This pharmacological property limits efficacy in very severe pain, but is advantageous for safety regarding respiratory depression.
Sources
- Gelbe Liste, Nalbuphine active ingredient profile
- AWMF S3 guideline labor analgesia and postoperative pain management
- BfArM, Federal Institute for Drugs and Medical Devices
- EMA product information nalbuphine preparations (international)
Legal Notice and Disclaimer
The information provided on this page is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medications should always be taken only on medical prescription or under pharmacy supervision. All information is based on expert information published at the time of preparation and recognized scientific sources; the current product information from the manufacturer is always authoritative. Sanoliste assumes no liability for completeness, timeliness, or accuracy of the information presented. In a medical emergency, call emergency number 112.